Xenon Launches Phase 3 for Seizures

 Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the launch of its XEN1101 Phase 3 program with the initiation of the X-TOLE2 clinical trial, which will examine XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy.

https://www.biospace.com/article/releases/xenon-pharmaceuticals-announces-launch-of-xen1101-phase-3-program-with-initiation-of-x-tole2-clinical-trial-in-patients-with-focal-onset-seizures/